Trial reportClinical and experimental rheumatology
A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients.
Trial report in Clinical and experimental rheumatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00883129 (Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease), which is not on this map. Cited by 95 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Who cites it
95 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of the role of quantitative CT in the prognostication and disease monitoring of interstitial lung disease.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Improved quality of life, reduced quantitative lung fibrosis in a trial of inhaled pirfenidone for idiopathic pulmonary fibrosis.BMC pulmonary medicine · 2026Trial
- Abatacept for the treatment of myositis-associated interstitial lung disease.Rheumatology (Oxford, England) · 2025Trial
- Associations between 6-minute walk distance and physiologic measures and clinical outcomes in myositis-associated interstitial lung disease.Rheumatology (Oxford, England) · 2025Trial
- Trial
- Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Trial
- Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial.American journal of respiratory and critical care medicine · 2024Trial
- LPARespiratory research · 2022Trial
- Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2021Trial
- The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis.Seminars in arthritis and rheumatism · 2020Trial
- Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.Annals of the American Thoracic Society · 2018Trial
- Trial
- Trial
- Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.The Lancet. Respiratory medicine · 2016Trial
- Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials.Arthritis research & therapy · 2015Trial
- Trial
- Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide.European radiology · 2011Trial
- The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis.Therapeutic advances in respiratory diseaseTrial
- Contemporary Concise Review 2025: Interstitial Lung Disease.Respirology (Carlton, Vic.) · 2026Review
- Automated identification of interstitial lung abnormalities in lung screening using quantitative CT.BMJ open respiratory research · 2026Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesTo evaluate an improved quantitative lung fibrosis score based on a computer-aided diagnosis (CAD) system that classifies CT pixels with the visual semi-quantitative pulmonary fibrosis score in patients with scleroderma-related interstitial lung disease (SSc-ILD).
methodsHigh-resolution, thin-section CT images were obtained and analysed on 129 subjects with SSc-ILD (36 men, 93 women; mean age 48.8±12.1 years) who underwent baseline CT in the prone position at full inspiration. The CAD system segmented each lung of each patient into 3 zones. A quantitative lung fibrosis (QLF) score was established via 5 steps: 1) images were denoised; 2) images were grid sampled; 3) the characteristics of grid intensities were converted into texture features; 4) texture features classified pixels as fibrotic or non-fibrotic, with fibrosis defined by a reticular pattern with architectural distortion; and 5) fibrotic pixels were reported as percentages. Quantitative scores were obtained from 709 zones with complete data and then compared with ordinal scores from two independent expert radiologists. ROC curve analyses were used to measure performance.
resultsWhen the two radiologists agreed that fibrosis affected more than 1% or 25% of a zone or zones, the areas under the ROC curves for QLF score were 0.86 and 0.96, respectively.
conclusionsOur technique exhibited good accuracy for detecting fibrosis at a threshold of both 1% (i.e. presence or absence of pulmonary fibrosis) and a clinically meaningful threshold of 25% extent of fibrosis in patients with SSc-ILD.
Indexed as
Identifiers
21050542PMC3177564What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.